Bright Minds Biosciences (DRUG) Cash & Current Investments (2020 - 2026)

Bright Minds Biosciences has reported Cash & Current Investments for 7 years, with the latest figure at $60.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 1397.16% year-over-year to $60.6 million; the trailing twelve-month figure through Mar 2026 stood at $60.6 million (up 1397.16% YoY), and the FY2025 full-year result was $60.3 million, up 1316.87% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $60.6 million, up from $59.6 million in the prior quarter.
• The five-year high for Cash & Current Investments was $60.6 million in Q1 2026, with the low at $4.0 million in Q1 2025.
• Historically, Cash & Current Investments has averaged $16.7 million across 5 years, with a median of $8.6 million in 2022.
• The largest YoY upside for Cash & Current Investments was 2379.04% in 2022 against a maximum downside of 45.19% in 2022.
• Bright Minds Biosciences' Cash & Current Investments stood at $8.6 million in 2022, then slumped by 41.83% to $5.0 million in 2023, then declined by 17.2% to $4.2 million in 2024, then jumped by 1333.34% to $59.6 million in 2025, then gained by 1.69% to $60.6 million in 2026.
• The last three Cash & Current Investments figures came in at $60.6 million (Q1 2026), $59.6 million (Q4 2025), and $60.3 million (Q3 2025), per Business Quant data.